ABPI Logo
  • Developing medicines
    • Responding to COVID-19
    • Clinical trials and research
    • Building a thriving environment for medicine discovery
    • UK-EU Future Relationship
    • Life Sciences Industrial Strategy
    • ABPI Medical Representatives Exam
  • Accessing medicines
    • How medicines are priced in the UK
    • Working with the NHS
    • Supply chain
    • Antimicrobial resistance (AMR)
    • Vaccines
    • What is the NICE Methods Review?
    • Rare diseases: Facing three challenges
  • Our ethics
    • ABPI Code of Practice
    • Disclosure UK
    • Appropriate prescribing
    • Patient & public involvement
  • Member representation
    • Events
    • Full membership
    • Working with our members​
    • ABPI Members List
    • Membership benefits
  • Who We Are
  • Media
  • Publications
  • Facts and Figures
  • Contact Us
  • ABPI Meetings (Adam.ai)
MY ABPI LOGIN
 
  • The Association of the British Pharmaceutical Industry
  • Developing medicines
  • UK-EU Future Relationship

UK-EU Future Relationship

­­­The ABPI is working to ensure that the UK has the best relationship with the EU for patients, public health and the life sciences sector.

Both sides have agreed to explore medicines cooperation in the Political Declaration. This ambition remains both in the UK Government’s negotiating objectives and in the EU Commission’s negotiating mandate.

We believe this should be a priority and are optimistic that both sides will be pragmatic about the need to work together on some essential aspects of medicines regulation.

Asks
What do we think the future EU-UK relationship should look like?

We also share the Government’s ambition of making the UK a leading global hub for life sciences and an internationally competitive trading partner with the EU and the world. For us, securing our reputation as an attractive destination for global investment is key, but as an industry, our priority is a future trading relationship with the EU based on cooperation.

What has the UK Government outlined?

The Government has set out a vision for a future relationship where both sides can work together in the interest of patient safety, public health, and the pursuit of scientific progress for UK and EU citizens. Its priorities for the UK-EU relationship, published in February 2020, include:

  • A Mutual Recognition Agreement (MRA) on batch testing and GMP.
  • Commitment on Good Regulatory Practice and Regulatory Cooperation.
  • Commitment to cooperate on pharmacovigilance.
  • Explore participation in Horizon programme.
  • No tariffs, fees, charges and quantitative restrictions on trade in manufactured and agricultural goods between the UK and the EU.

We have responded to these priorities here.

EFPIA Brexit Taskforce

Given the integrated nature of research, regulation and supply of medicines across Europe, the ABPI is working closely with the European Federation of Pharmaceutical Industries and Associations (EFPIA), who have established a Brexit Taskforce.

Key documents

  • ABPI Brexit Manifesto document, June 2016
  • Maintaining and growing the UK’s world leading Life Sciences sector in the context of leaving the EU, September 2016
  • OHE Research into Public Health and Economic Implications of the United Kingdom Exiting the EU and the Single Market, December 2017
  • Life Science Industry Coalition Position Paper, December 2017
  • Brexit Health Alliance Briefing on Brexit and the impact on patient access to medicines and medical technologies, January 2018

 

Developing medicines

  • Building a thriving environment for medicine discovery
  • Responding to COVID-19
  • UK-EU Future Relationship
    • What do we think the future EU-UK relationship should look like?
    • Ending the transition period with new border arrangements
  • Life Sciences Industrial Strategy
  • 2020 Manifesto for Medicine
  • New medicines & data
  • Academic collaboration, education & skills
  • Regulatory science
  • Clinical trials and research

ABPI

The Association of the British Pharmaceutical Industry is a company limited by guarantee registered in England and Wales 
(registered number 09826787) and its registered office is at 7th Floor Southside,105 Victoria Street, London, SW1E 6QT.
Telephone +44 (0) 207 9303477

© ABPI 2021
  • Twitter Logo
  • LinkedIn
  • YouTube Logo

Devolved Nations

  • Cymru Wales
  • Northern Ireland
  • Scotland

Quick Links

  • ABPI Exam
  • Disclosure UK
  • Frequently Asked Questions
  • Careers
  • Schools
  • Acronym buster

Website Info

  • Terms and conditions
  • Accessibility
  • Cookie Policy

Prescription Medicines Code of Practice Authority (PMCPA)

The Prescription Medicines Code of Practice Authority (PMCPA) was established by The Association of the British Pharmaceutical Industry to operate the ABPI Code of Practice for the Pharmaceutical Industry independently of the ABPI. The PMCPA is a division of ABPI which is a company registered in England and Wales (registered number 09826787) with its registered office at 7th Floor, Southside, 105 Victoria Street, London SW1E 6QT.

Office of Health Economics (OHE)

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 7th Floor Southside, 105 Victoria Street, London, SW1E 6QT. OHE provides independent research, advisory and consultancy services on policy implications and economic issues within the pharmaceutical, health care and biotechnology sectors.